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The presenilins (PS1 and PS2) are the catalytic component of the c-secretase intramembrane pro-
tease complex, involved in the regulated intramembrane proteolysis of numerous type I transmem-
brane proteins, including amyloid precursor protein (APP) and Notch. Herein, we describe the
identiﬁcation and characterization of a CUE (coupling of ubiquitin conjugation to endoplasmic
reticulum degradation) ubiquitin-binding domain (UBD) in PS1, and demonstrate that the CUE
domain of PS1 mediates non-covalent binding to Lysine 63-linked polyubiquitin chains. Our results
highlight a c-secretase-independent function for non-covalent ubiquitin signaling in the regulation
of PS1, and add new insights into the structure and function of the presenilin proteins.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The reversible covalent attachment of the 8kDa protein ubiqui-
tin (Ub) to cellular proteins, predominantly to primary amines (e-
amino groups of Lys and to the N termini of proteins) targets pro-
teins for proteasomal degradation and also facilitates several non-
proteasomal functions in the assembly, ampliﬁcation and trans-
mission of intracellular signals [1–4]. Protein ubiquitination is
the culmination of a multistep process involving three classes of
enzymes, known as ubiquitin-activating enzymes (E1), ubiquitin-
conjugating enzymes (E2s), and substrate-speciﬁc ubiquitin pro-
tein ligases (E3) [4]. Proteins may be ubiquitinated on a single
lysine, resulting in monoubiquitination or on several lysine resi-
dues resulting in multiubiquitination. In addition, some E2/E3
combinations can then use lysines on the substrate-conjugated
ubiquitin to act as acceptors during sequential rounds of ubiquiti-
nation, resulting in substrate polyubiquitination [5]. Ub contains
seven lysines, which can be utilized during polyubiquitin chainformation and depending on which of the seven lysines act as
the acceptor, the ubiquitin chains will have different types of link-
ages with diverse conformations and create a diversity of molecu-
larly distinct signals in the cell [4,6]. The range of substrate-
ubiquitin structures is important for the targeting of ubiquitinated
substrates to different fates. For example, K11- and K48-linked
polyubiquitin chains generally target proteins for proteasomal
degradation [7], while K63-linked chains can regulate kinase
activation, DNA damage tolerance, signal transduction, and endo-
cytosis [8,9].
Modulation of protein–protein interactions is an important
mechanism involved in the assembly, ampliﬁcation and transmis-
sion of intracellular signals. The recognition of ubiquitin and
polyubiquitin chains by ubiquitin-binding domains (UBDs) is criti-
cal for determining the outcome of ubiquitination and subsequent
ubiquitin-mediated signaling pathways [2]. To date, approximately
20 different UBDs have been identiﬁed, including ubiquitin inter-
acting motifs (UIMs), ubiquitin associated domains (UBAs) and
the related coupling of ubiquitin conjugation to endoplasmic
reticulum degradation (CUE) domains [10–12]. The UBA and CUE
domains are similar in size, approximately 40 residues, and show
a common structural homology consisting of a three helical bundle
[10]. The CUE domain was initially characterized as an ubiquitin-
binding motif and named for the yeast Cue1p protein, which is
essential for the targeting of ubiquitinated protein to degradation
pathways [13–15]. Functional studies subsequently revealed that
CUE domains promote the ubiquitination of the proteins that
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contribute to the stability and speciﬁcity of the CUE–ubiquitin
complex, and moreover that CUE domain containing proteins play
an important role in stabilizing its binding partner [16,17]. The CUE
domain of other proteins has been shown to mediate interactions
between ubiquitin and CUE domain containing proteins, which
facilitates their monoubiquitination [18–20].
The presenilins, PS1 and PS2, are highly conserved transmem-
brane proteins that are synthesised as 50kDa holoproteins that
undergo endoproteolysis to generate heterodimeric presenilin N-
terminal and C-terminal fragments (NTF/CTF) that form the cat-
alytic subunit of the c-secretase protease complex. Initially
characterized as a protease responsible for the cleavage of amyloid
precursor protein (APP) and the generation of amyloid-b peptides,
the c-secretase protease is now known to be responsible for the
cleavage of numerous type I transmembrane proteins associated
with several developmental and cellular processes, including the
Notch receptor, ErbB4, Cadherins, Insulin-like growth factor recep-
tor (IGFR1) [21] and the interleukin-1 receptors, IL-1RI [22,23] and
IL-1RII [24]. In addition to the well-researched role of presenilins
as the catalytic core of the c-secretase protease, the involvement
of presenilin holoproteins in the regulation of intracellular calcium
homeostasis has become a focus of presenilin and Alzheimer’s dis-
ease research [25–28].
Critical to the complexity of presenilin-associated activities, PS1
and PS2 are differentially controlled by post-translational mod-
iﬁcations including endoproteolysis, caspase cleavage, phospho-
rylation and ubiquitination [29]. These modiﬁcations determine
subcellular localisation [30], selectivity of binding-partners, rate
of protein turnover [31] and c-secretase protease activity [32,33].
PS1 is ubiquitinated by SEL-10 and tumor necrosis factor receptor
associated factor 6 (TRAF6), which regulate c-secretase activity
and calcium homeostasis [34], respectively. Here we report the
identiﬁcation and characterization of a ubiquitin binding CUE
domain in PS1, which facilitates the binding of PS1 to K63-linked
polyubiquitin chains.
2. Materials and methods
2.1. Cell culture and transfection
HEK293T and presenilin-deﬁcient murine embryonic ﬁbrob-
lasts (MEFs) cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM-21) supplemented 10% fetal bovine serum at
37 C. Transfection of HEK293T and MEFs was performed using
the calcium phosphate precipitation method and TurboFect™
(BioRad Laboratories), respectively.
2.2. Expression vectors construction
The pcDNA3.1-PS1 expression construct was described pre-
viously [35,36]. PS1DCUE, PS1F283A/P284A and PS1V309A/
S310A, were generated by site-directed mutagenesis using
QuickChange Site Directed Mutagenesis Kit (Stratagene) and the
following primers: PS1DCUE: GATTTAGTGGCTTATAATGCAGAA
AGCACAGAA (sense) and TTCTGCATTATAAGCCACTAAATCATATAC
TGA (antisense); PS1: CGGGGTACCGCCATGACAGAGTTACCTGCA
CCGTTGTCC (sense) and CCGGAATTCCTAGATATAAAATTGATGGA
ATGCTAATTG (antisense); PS1F283A/P284A: GAGAAATGAAACGCT
TGCTGCAGCTCTCATTTACTCC (sense) and GGAGTAAATGAGAG
CTGCAGCAAGCGTTTCATTTCTC (antisense); PS1V309A/S310A:
GGAAGCTCAAAGGAGAGCAGCCAAAAATTCCAAG (sense) and
CTTGGAATTTTTGGCTGCTCTCCTTTGAGCTTCC (antisense). Position
of mutated sites are underlined. GST-fusion proteins, GST-PS1
loop domain (residues 265–380), GST-PS1F283A/P284A andGST-PS1V309A/S310A loop domain mutants were ampliﬁed by
PCR (KOD polymerase, Novagen) using CGGGGATCCGCCGTTTT
GTGTCCGAAAGGT (sense) and CCGGAATTCCTATTTTACTCCCCTTT
CCTC (antisense) and subcloned into pGEX-6P-1 GST expression
vector (GE Healthcare). HA-ubiquitin, HA-ubiquitin K48only and
HA-ubiquitin K63only were a generous gift from Dr. R. Carmody
(University of Glasgow). HA-P62 was a gift from Prof. Jorge
Moscat & Dr. Marie Wooten (Sanford Burnham Medical research
Institute, CA), and the HA-P62 F406V mutant was generated by
site-directed mutagenesis using previously published primer pairs
[37]. The NEXT (Notch extracellular truncation) expression plasmid
was a gift from Raphael Kopan (Washington University) [38].
APP-CT100 was a gift from Scios Inc.
2.3. Western blot analysis
Total or immunoprecipitated protein extracts were obtained
from cells 24–48 h after transfection with speciﬁc plasmids. Cells
were lysed (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1%
Nonidet P-40, 1 mM sodium orthovanadate and protease inhibitor
mixture (Complete™, Roche Molecular Biochemicals)) and protein
concentrations in the extracts were measured with a bicinchoninic
acid assay (Pierce). Equal amounts of extracts were resolved on 6%,
10%, 12% or 15% SDS–PAGE and transferred to nitrocellulose mem-
brane. Immunoblot analysis was performed with anti-PS1 NTF
[39], anti-PS1-NTF (Chemicon), anti-HA (Covance), anti-APP
(Sigma Aldrich), anti-Ubiquitin (P4D1, Santa Cruz Biotechnology),
anti-b-actin (Sigma Aldrich) and anti-cleaved Notch 1 (Val 1744)
(Cell Signaling Technology) antibodies, followed by incubation
with secondary horseradish peroxidase-labeled anti-mouse, anti-
rabbit (Dako), or infrared secondary antibodies IRDye 800 Goat
Anti-Rabbit IgG or IRDye 800CW Goat Anti-Mouse IgG (Licor
Biosciences).
2.4. In vitro ubiquitin binding assay
For the whole-cell ubiquitin binding studies, cells expressing
the indicated proteins were lysed under stringent denaturing con-
ditions and immunopuriﬁed with anti-P62, or PS1 antibodies and
protein G-sepharose beads (Invitrogen) and subsequently washed
3 times with covalent buffer (50 mM Tris (pH 8.0), 150 mM NaCl,
1% Triton, 0.1% SDS, 0.5% sodium deoxycholate, 15 mM NEM and
protease inhibitors) and once with binding buffer (20 mM Tris–
HCl (pH 7.6), 50 mM NaCl, 0.1% NP40, 0.5 mM dithiothreitol,
1 mM phenylmethylsulfonyl ﬂuoride). Samples were incubated
overnight at 4 C in binding buffer with 5 lg of polyubiquitin
(K48- or K63-linked) (Boston Biochem), washed with binding buf-
fer and loaded onto a 10% SDS–PAGE, recombinant polyubiquitin
(K48- or K63-linked) (1 lg) was used as a positive control, fol-
lowed by Western blotting analysis using an antibody directed
against ubiquitin (P4D1, Santa Cruz Biotechnology).
For the in vitro ubiquitin binding assays, recombinant (20 lg)
GST-PS1 loop domain, GST-PS1F283A/P284A or GST-PS1V309A/
S310A loop domain mutants were immobilized onto glutathione
agarose beads (Sigma Aldrich) and incubated with 800 lg total
protein extracted from HEK293T cells, either non-transfected or
overexpressing HA-Ub-K48only or HA-Ub-K63only lysed in binding
buffer. Samples were incubated overnight at 4 C, washed in bind-
ing buffer and loaded onto SDS–PAGE followed by Western blot-
ting analysis with an antibody directed against ubiquitin (P4D1,
Santa Cruz Biotechnology).
2.5. Expression and puriﬁcation of GST-tagged recombinant proteins
The pGEX-6P-1 GST-PS1 loop domain (residues 265-380),
pGEX-6P-1 GST-PS1F283A/P284A and pGEX-6P-1 GST-PS1V309A/
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into the Escherichia coli strain BL21-CodonPlus (DE3)-RIL
(Stratagene) for recombinant protein expression. Induction of
expression, glutathione agarose afﬁnity chromatography and puri-
ﬁcation of the recombinant proteins was performed using pre-
viously established methods [40]. The purity and molecular
weight of the recombinant protein samples were analyzed by
SDS–PAGE. The protein concentration was determined from UV
absorbance at 280 nm.
2.6. ELISA for Ab40 and Ab42
HEK293T cells were transfected by calcium phosphate precip-
itation with indicated constructs. Thirty-six hours after transfec-
tion, cell culture medium was collected for ELISA analysis and
cells were subjected to Western blotting. ELISA kits for Ab40
and Ab42 were purchased from Invitrogen (#KHB3481 and
#KHB3441). ELISA analyses were carried out according to the
manufacturer’s protocol.
2.7. Statistical analysis
Microsoft Excel was used for the statistical analysis. Data are
shown as means + standard error (S.E.M.) of replicate samples in
at least three independent experiments. Student’s t-test was usedJNet secondary structure
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3. Results
3.1. Presenilins contain a highly conserved putative CUE ubiquitin-
binding domain
To further examine the posttranslational modiﬁcation of prese-
nilins, the amino acid sequences of PS1 and PS2 hydrophilic loop
domains were analyzed by sequence analysis. This revealed a
low-homology between the hydrophilic loop domain of PS1 and
the CUE ubiquitin-binding domain of several proteins (Fig. 1). A
sequence alignment of the hydrophilic loop domain of PS1 and
PS2 with several known CUE domains revealed a high conservation
of a methionine–phenylalanine–proline and to a lesser extent a di-
leucine motif, characteristic of CUE ubiquitin-binding domains, as
well as a number of other hydrophobic residues thought to be
important for non-covalent interaction with ubiquitin (Fig. 1B). A
sequence alignment of this region of PS1 among several species
demonstrates strong evolutionary conservation of the sequence
surrounding and including the phenylalanine–proline motif and a
weaker conservation of the sequence containing the PS1 valine–
serine sequence which corresponds to the position of the di-leucine
motif, present in some, but not all CUE domains (Fig. 1C). The CUEY S S A M V W T V G M A K L D P S S Q G A L Q
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and is comprised of a three-helix bundle. Using JNET, www.comp-
bio.dundee.ac.uk [41], secondary protein structure prediction soft-
ware, the putative CUE domains of PS1 and PS2 were predicted to
contain three consecutive a-helices, with the conserved methion-
ine–phenylalanine–proline residues located close to a-helix 1 and
the PS1 valine–serine sequence residing in ahelix 3 (Fig. 1B).
Given that this sequence conservation and predicted structural
arrangement are shared by the putative CUE domain of presenilins
and several other CUE domains, it supports our hypothesis that the
newly identiﬁed CUE domain in presenilins may mediate interac-
tions between presenilins and ubiquitinated substrates.
3.2. Presenilins non-covalently interact with K63-linked polyubiquitin
To determine whether presenilins interact non-covalently with
ubiquitin and contain functional CUE ubiquitin-binding domains,
HEK293T cells were transfected with pcDNA3.1, pcDNA3.1-PS1 or
pcDNA3.1-PS1DCUE (Fig. 2A), and 24 h post-transfection cells
were harvested under denaturing conditions and the cell lysates
were immunoprecipitated with an anti-PS1 antibody. The
immunoprecipitates were then incubated overnight with recombi-
nant lysine 63 (K63)-linked or lysine 48 (K48)-linked polyubiquitin
and after stringent washing ubiquitin-binding was determined by
western blotting. Our data demonstrates that PS1 has a preferenceEV
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Fig. 2. Presenilins selectively interact with K63-linked polyubiquitin. HEK293T
cells expressing wild type or mutant (A) PS1 (B) P62 were lysed under stringent
denaturing condition, immunopuriﬁed and incubated with 5 lg of recombinant
K48-linked or K63-linked polyubiquitin, and bound proteins resolved by SDS–PAGE
and immunoblotted with antibodies against ubiquitin (PD41), PS1 or P62. Loading
control for recombinant lysine 63 (K63)-linked (1 lg) or lysine 48 (K48)-linked
polyubiquitin (1 lg) used in experiments is also indicated (right panels). IP,
immunoprecipitated; WB, Western blot; HC, IgG heavy chain; LC, IgG light chain.for binding K63-linked over K48-linked polyubiquitin chains
(Fig. 2A). In contrast, no binding to K63-linked polyubiquitin to
PS1 was observed in the PS1DCUE mutant. Loading control for
recombinant lysine 63 (K63)-linked or lysine 48 (K48)-linked
polyubiquitin used in experiment is indicated (Fig. 2A, right panel).
To validate the in vitro ubiquitin-binding assay employed in these
studies, the ability of PS1 to bind polyubiquitin was compared to
that of P62/sequestosome 1, which contains a functional UBA
domain that binds to K63-linked polyubiquitin [42]. A single point
mutation within the UBA domain of P62, P62F406V, abolishes ubi-
quitin binding to the P62 UBA domain. Consistent with previous
studies, wild type P62 but not P62F406V bound to K63-linked
polyubiquitin (Fig. 2B). Loading control for recombinant lysine 63
(K63)-linked polyubiquitin used in experiment is indicated
(Fig. 2B, right panel). Together these results demonstrate that PS1
contains a functional ubiquitin-binding domain that has a prefer-
ence for binding K63-linked polyubiquitin.
Based on sequences predicted to be important for ubiquitin
binding to other CUE domains, we used a site-directed mutagene-
sis approach to generate mammalian expression constructs of the
PS1 CUE missense mutants PS1F283A/P284A and PS1V309A/
S310A. Previous studies demonstrated that mutation of the con-
served methionine–phenylalanine–proline and di-leucine motifs
reduce the ability of the CUE domain of speciﬁc proteins to interact
with ubiquitin [43]. JNet secondary structure prediction analysis
revealed that the triple helical super-secondary structure of the
CUE domain should not be disrupted by these mutations (data
not shown). HEK293T cells were transiently transfected with equal
quantities of pcDNA3.1 (Vector), wild type PS1, PS1DCUE,
PS1F283A/P284A or PS1V309A/S310A. The PS1 proteins were iso-
lated using immunoprecipitation and were then incubated with
recombinant K63-linked polyubiquitin (Fig. 3A). Western blotting
analysis revealed that wild-type PS1 and the PS1 F283A/P284A
mutant bound to ubiquitin, while in contrast the PS1DCUE and
PS1V309A/S310A mutants had reduced interaction with K63-
linked polyubiquitin (Fig. 3A). These results suggest that the K63-
linked polyubiquitin binding capability of the putative CUE of
PS1 is mediated by the VS sequence, while the FP motif does not
appear to be as important in PS1 binding to K63-linked polyu-
biquitin as it shows a similar level of ubiquitin-binding as wild-
type PS1.
To further examine the ubiquitin binding ability of the PS1 CUE
domain, three GST-tagged recombinant proteins were created: a
GST-PS1 loop domain protein (residues 265–280) containing the
CUE domain, GST-PS1F283A/P284A and GST-PS1V309A/S310A
loop domain mutants. The recombinant proteins were bound to
glutathione agarose beads and then incubated with cell lysate from
cells overexpressing HA-ubiquitin K63only, a ubiquitin mutant that
can only form K63-linked polyubiquitin chains within cells [44].
GST protein was used as negative control for this experiment.
The resulting samples were run on a 10% SDS–PAGE gel and the
presence of bound ubiquitin was detected by immunoblotting for
HA. Consistent with data presented (Fig. 3A), the GST-PS1 loop
domain fusion protein and GST-PS1F283A/P284A mutant bound
to K63-linked polyubiquitin, while the GST-PS1V309A/S310A loop
domain mutant lost the ability to bind K63-linked polyubiquitin
(Fig. 3B). To verify PS1 selectivity for binding to K63-linked ubiqui-
tin in our in vitro assay, next, recombinant GST-PS1 loop domain
protein and GST-PS1V309A/S310A mutant were bound to glu-
tathione agarose beads and then incubated with cell lysate from
cells overexpressing ubiquitin K48only or ubiquitin K63only,
(Fig. 3C). Again, the GST-PS1 loop domain fusion protein selectively
bound to K63-linked polyubiquitin and not K48-linked polyu-
biquitin, while the GST-PS1V309A/S310A mutant lost the ability
to bind K63-linked polyubiquitin (Fig. 3C).
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Next we determined if the CUE domain was required for prese-
nilin endoproteolysis and c-secretase activity. Given that the CUE
domain (residues 271–314) of PS1 is located within the large
hydrophilic loop domain and spans the sites of presenilin
endoproteolysis (PS1 Met292/Val293) [32,45], we examined thepossible involvement of the putative CUE domain in endoproteoly-
sis of PS1 by deletion of the entire CUE domain from PS1
(PS1DCUE) and mutagenesis of the two conserved motifs within
the PS1 CUE domain (PS1F283A/P284A and PS1V309A/S310A).
Presenilin double knockout murine embryonic ﬁbroblasts were
transfected with expression constructs directing the synthesis of
wild-type PS1, catalytically inactive PS1D257A/D385A (PS1DAsp)
mutant, CUE domain deletion mutant PS1DCUE, or CUE domain
point mutants PS1F283A/P284A or PS1V309A/S310A. Cell lysates
were immunoblotted with anti-PS1 NTF antibody (Fig. 4A). As
anticipated, expression of the catalytically inactive PS1D257A/
D385A (PS1DAsp) mutant, or deletion of PS1 CUE domain pre-
vented the endoproteolysis of PS1, and abolished the formation
of PS1 endoproteolytic NTF fragment (Fig. 4A). However, expres-
sion of the PS1 CUE domain point mutants PS1F283A/P284A and
PS1V309A/S310A had no effect on PS1 endoproteolysis and forma-
tion of PS1 NTF fragment.
Presenilin holoprotein undergoes endoproteolysis into NTF/CTF
heterodimers and has been predominantly studied as a component
of the c-secretase protease complex involved in the regulated
intramembrane proteolysis of APP, Notch and several other type I
integral membrane proteins [46]. We next measured c-secretase
activity in cells expressing CUE mutants by studying the cleavage
of a truncated APP mutation (APP CT100-FLAG), which corresponds
to the b-secretase generated APP C99 C-terminus fragment, which
is a constitutive substrate for c-secretase protease. First, HEK293T
cells, were transiently transfected with APP CT100-FLAG plasmid
and co-transfected with pcDNA3.1 (Vector), PS1, PS1DCUE
PS1F283A/P284A or PS1V309A/S310A and cell lysates were sub-
jected to Western blot analysis with an anti-APP C-terminus-speci-
ﬁc antibody (Fig. 4B). In cells expressing PS1, overexpressed APP
C99-FLAG fragment is clearly detected (Fig. 4B, lane 3). In cells
expressing PS1 and treated with the c-secretase inhibitor,
Compound E, accumulation of overexpressed APP C99-FLAG and
endogenous APP C99 fragments are clearly detected (Fig. 4B, lane
4). In contrast, expression of PS1 CUE mutants did not alter levels
of exogenous APP C99-FLAG nor endogenous APP C99 C-terminal
fragment, which indicates that CUE domain deletion does not
induce a major change in c-secretase activity (Fig. 4B). To further
conﬁrm the result with a more sensitive method, cell culture med-
iumwas collected after transfection and tested using ELISA to mea-
sure the concentration of Ab40 and Ab42 (Fig. 4C). Results showed
that CUE domain deletion or mutagenesis does not induce signiﬁ-
cant change in the generation of soluble Ab40 and Ab42. To further
validate this observation, PS1-deﬁcient MEFs were transiently
transfected with pcDNA3 (Vector), PS1, PS1DCUE PS1F283A/
P284A or PS1V309A/S310A and cell lysates were analyzed for
endogenous APP C99, by Western blotting with an APP C-termi-
nus-speciﬁc antibody (Fig. 4D). Again, expression of the CUE
mutants had no effect on levels of endogenous APP C99, whereas
treatment with the c-secretase inhibitor Compound E (lane 3)
caused the accumulation of the APP C99 fragment, again demon-
strating that loss of or mutagenesis of the PS1 CUE domain does
not signiﬁcantly alter c-secretase cleavage of APP.
To further examine the functionality of the PS1 CUE domain in
the cleavage of c-secretase substates. HEK293T cells, were tran-
siently transfected with NEXT, a Notch construct that is con-
stitutively cleaved by c-secretase, and co-transfected with
pcDNA3 (Vector), wild-type PS1, PS1DCUE, PS1F283A/P284A or
PS1V309A/S310A. Twenty-four hours post-transfection cell lysates
were prepared and subjected toWestern blot analysis with an anti-
cleaved Notch 1 speciﬁc antibody (Fig. 4E). In cells expressing PS1,
robust generation of NICD was evident (Fig. 4E, lane 3), while in
cells treated with the c-secretase inhibitor, compound E (CpdE)
(Fig. 4E, lane 4) formation of NICD was inhibited. In contrast, in
cells expressing PS1DCUE, PS1F283A/P284A or PS1V309A/S310A,
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Fig. 4. Presenilins CUE domain is dispensable for c-secretase activity. (A) Western blot analysis of total cell lysates from presenilin-deﬁcient MEFs transiently expressing
pcDNA3.1 (Vector) wild type PS1, catalytically inactive PS1D257A/D385A (PS1DAsp) mutant, PS1DCUE, PS1F283A/P284A or PS1S310A/V309A. (B) HEK293T cells were
transfected with APP CT100-FLAG and co-transfected with pcDNA3.1 (Vector) wild type PS1, PS1DCUE, PS1F283A/P284A or PS1V309A/S310A. Twelve hours after transfection,
selected cell cultures were treated with Compound E (50 nM) as indicated. Cells were harvested 24 h after transfection and lysates were subjected to western blot analysis
with anti-APP, anti-PS1 and anti-b-actin antibodies. (C) Culture medium was collected from HEK293T cells transfected with APP CT100-FLAG and co-transfected with
pcDNA3.1 (Vector) wild type PS1, PS1DCUE, PS1F283A/P284A or PS1V309A/S310A, and subjected to ELISA for Ab40 and Ab42. Data is presented by means ± S.E.M. of three
independent experiments. p < 0.05 was considered statistically signiﬁcant. (D) Western blot analysis of cell lysates from presenilin-deﬁcient MEFs transiently expressing
pcDNA3.1 (Vector) wild type PS1, PS1D257A/D385A, PS1DCUE, PS1F283A/P284A or PS1S310A/V309A. (E) HEK293T cells were transfected with NEXT expression plasmid and
co-transfected with pcDNA3.1 (Vector) wild type PS1, PS1D257A/D385A, PS1DCUE, PS1F283A/P284A or PS1V309A/S310A. Twelve hours after transfection selected cell
cultures were treated with Compound E (50 nM) as indicated. Cells were harvested 24 h after transfection. Lysates were subjected to SDS–PAGE and immunoblotted with
anti-cleaved Notch, anti-PS1 and anti-b-actin antibodies.
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the CUE domain of PS1 or mutagenesis of key motifs within the
PS1 CUE domain has no effect on the c-secretase mediated cleav-
age of Notch.
4. Discussion
Here we describe the presence of a CUE ubiquitin-binding
domain in the hydrophilic loop domain of presenilins, which facili-
tates an interaction between PS1 and K63-linked polyubiquitin
chains. Despite the signiﬁcant importance of presenilins as thecatalytic component of c-secretase protease complexes, its struc-
ture and posttranslational regulation are poorly understood. In
addition to endoproteolysis, presenilins are also regulated by
diverse posttranslational modiﬁcations including phosphorylation
[39,47,48] and ubiquitination [31,34], which alter the functions
of presenilins and their interaction with other proteins [29].
These modiﬁcations are not only essential for the stability and
activation of presenilins, but are also important for the protease
assembly and activity of c-secretase complexes. For instance,
SEL-10, a member of the SCF (Skp1-Cdc53/CUL1-F-box protein)
E2–E3 ubiquitin ligase family was shown to interact with and
S.P. Duggan et al. / FEBS Letters 589 (2015) 1001–1008 1007enhance PS1 ubiquitination, and alter the cellular levels of PS1
holoprotein and its NTF/CTF heterodimers [34]. In contrast, we
have also reported the ubiquitination of PS1 and PS2 by another
E3 ligase, tumor necrosis factor receptor-associated factor 6
(TRAF6) [35], which alters the stability of PS1 holoprotein and its
function in the regulation of calcium homeostasis, independent
of c-secretase protease activity.
Thus, the identiﬁcation of a CUE domain represents an impor-
tant advancement in the understanding of the posttranslational
activity in these biologically and therapeutically important pro-
teins. The CUE domain is structurally related to the ubiquitin-bind-
ing UBA domain and is strictly comprised of a three-helix bundle
structure (Fig. 1). However, the amino acid sequence of CUE
domains does differ from the consensus amino acid sequence, sug-
gesting that the structural integrity of the CUE domain rather that
amino acids sequence is the primary determinant for interaction
with different ubiquitin modiﬁcations. Within the CUE domain, a
conserved MFP motif in a-helix1 and a less conserved LL motif in
a-helix 3 have been shown to enable interaction with the con-
served hydrophobic patch of ubiquitin. While deletion of the entire
PS1 CUE domain abolished binding to ubiquitin, mutation of the
MFP motif in PS1 did not signiﬁcantly disrupt interaction with ubi-
quitin. However, mutagenesis of the PS1 VS sequences that corre-
sponds to the LL motif in a-helix 3 did disrupt binding to ubiquitin.
It was surprising that mutation of the MFP motif in PS1 did not dis-
rupt interaction with ubiquitin, as is the case for many published
CUE domain-containing proteins. These discrepancies suggest that
the PS1 CUE domain may bind to ubiquitin in a different manner.
Site-directed mutagenesis and deletion of residues predicted to
have an important role in non-covalent ubiquitin binding [43]
revealed and highlight the biological importance of this domain
in presenilins. First, using the CUE domain deletion and missense
CUE mutants demonstrated loss in ability of PS1 to selectively bind
to K63-linked polyubiquitin chains. Second, missense CUE mutants
that prevented binding to ubiquitin, did not affect endoproteolysis
of PS1, suggesting that formation of PS1NTF/CTF heterodimers does
not require an intact CUE domain, but suggest that the presence of
the CUE domain may be important for a PS1 holoprotein function.
Third, mutation of the CUE domain did not alter PS1-dependent c-
secretase cleave of APP or Notch, nor generation of Ab40/42 pep-
tides, suggesting that the PS1 CUE domain is not necessary for c-
secretase activity.
Recognition of ubiquitin and polyubiquitin chains by ubiquitin-
binding domains (UBDs) is vital for ubiquitin-mediated signaling
pathways [9]. The presenilins regulate critical proteins and bio-
logical functions via c-secretase dependent and independent
mechanisms [49]. Based on other studies that have elucidated
the function of CUE domains on other proteins, the presence of
the CUE domain in presenilins leads to at least three possible func-
tions of this CUE domain; ubiquitination of presenilin enables the
CUE domain to recognize and non-covalently interact with prese-
nilin itself (intraprotein interaction); ubiquitination of presenilin
leads to the formation of a presenilin homodimer enabled by inter-
action between the CUE domain and ubiquitinated presenilin on
an adjacent holoprotein, or the CUE domain of presenilins facili-
tates its interaction with other ubiquitin-modiﬁed proteins (inter-
protein interaction).
Taken together our results highlight a function for non-covalent
ubiquitin signaling in the regulation of the presenilins, add new
insight into the structure and function of the presenilins and have
important implications for cell signaling and Alzheimer’s disease.
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